Breast cancer

TRANS ROSALEE

A BIOMARKER-DIRECTED, TRANSLATIONAL STUDY OF HIGH-THROUGHPUT MOLECULAR PROFILING OF HR+/HER2- METASTATIC BREAST CANCER TREATED WITH ENDOCRINE THERAPY AND RIBOCICLIB.

Open at Paris since : 27/02/2024
Target : Adult
Phase : Phase III

Trial description

The primary objective of the study is to compare the prevalence of molecular alterations between post- versus pre-treatment tumour samples of advanced or metastatic HR+/HER2- BC patients for which both samples (paired post- and pre-treatment) are available.;Pre-treatment samples will be collected before initiation of ribociclib + ET treatment. Post-treatment samples will be collected after disease progression on ribociclib + ET treatment, and before initiation of a new therapeutic line.

Url of the trial

Main investigator

HELENE SALAUN

Médecin

Contact